Addex Therapeutics LTD. (ADXN) — SEC Filings

Overview

Addex Therapeutics LTD. (ADXN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 21, 2026: Addex Therapeutics Ltd. filed a Form 6-K on April 21, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1, detailing recent company activities and financial updates. The company's mailing and business address is CHEMIN DES MINES 9, GENEVA V8, CH-1202.

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 33 neutral. The dominant filing sentiment for Addex Therapeutics LTD. is neutral.

Filing Type Overview

Addex Therapeutics LTD. (ADXN) has filed 1 3, 28 6-K, 2 20-F, 2 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (33)

• Addex Therapeutics Files 6-K Report — 6-K · Apr 21, 2026 Risk: low
  Addex Therapeutics Ltd. filed a Form 6-K on April 21, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1, deta
• Addex Therapeutics: Roger Mills Files Form 3, Signals Insider Ownership — 3 · Mar 25, 2026
  Roger Mills, a new insider at Addex Therapeutics Ltd. (ADXN), filed a Form 3 on March 25, 2026, indicating his initial beneficial ownership of securities as of
• 6-K Filing — 6-K · Dec 10, 2025
• 6-K Filing — 6-K · Dec 4, 2025
• Addex Therapeutics Files 6-K with Press Release — 6-K · Oct 29, 2025 Risk: low
  On October 29, 2025, Addex Therapeutics Ltd. issued a press release that is incorporated by reference into their Form 6-K filing. This press release is also bei
• Addex Therapeutics Files 6-K, Incorporates Exhibits — 6-K · Sep 30, 2025 Risk: low
  Addex Therapeutics Ltd. filed a Form 6-K on September 30, 2025, reporting on its activities as of June 30, 2025. The filing incorporates by reference exhibits 9
• Addex Therapeutics Files Form 6-K with Press Release — 6-K · Sep 23, 2025 Risk: low
  On September 23, 2025, Addex Therapeutics Ltd. issued a press release, attached as Exhibit 99.1 to this Form 6-K filing. This press release is incorporated by r
• Addex Therapeutics Files 6-K with Press Release — 6-K · Jun 30, 2025 Risk: low
  On June 30, 2025, Addex Therapeutics Ltd. filed a Form 6-K to report the issuance of a press release. This press release, dated June 30, 2025, is attached as Ex
• Addex Therapeutics Files Form 6-K with SEC — 6-K · Jun 25, 2025 Risk: low
  On June 25, 2025, Addex Therapeutics Ltd. announced the issuance of a press release, incorporated by reference as Exhibit 99.1 to this Form 6-K filing. This pre
• Addex Therapeutics Files 6-K, Incorporates Exhibits — 6-K · Jun 20, 2025 Risk: low
  Addex Therapeutics Ltd. filed a Form 6-K on June 20, 2025, incorporating by reference Exhibits 99.1 and 99.2 into its existing registration statements on Form F
• Addex Therapeutics Files 6-K with Press Release — 6-K · Jun 6, 2025 Risk: low
  On June 6, 2025, Addex Therapeutics Ltd. issued a press release, incorporated as Exhibit 99.1 to this Form 6-K filing. This press release is being incorporated
• Addex Therapeutics Files 2024 Annual Report — 20-F · May 15, 2025 Risk: medium
  Addex Therapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, incorporated in V8 and headquartered in
• Addex Therapeutics Files 6-K with Press Release — 6-K · May 12, 2025 Risk: low
  On May 12, 2025, Addex Therapeutics Ltd. issued a press release, attached as Exhibit 99.1 to this Form 6-K filing. This press release is incorporated by referen
• Addex Therapeutics Files 6-K with Press Release — 6-K · Apr 30, 2025 Risk: low
  On April 30, 2025, Addex Therapeutics Ltd. issued a press release, attached as Exhibit 99.1 to this Form 6-K filing. This press release is incorporated by refer
• Addex Therapeutics Files 6-K, Incorporates Press Release — 6-K · Apr 25, 2025 Risk: low
  On April 25, 2025, Addex Therapeutics Ltd. announced the issuance of a press release, which is incorporated by reference into this Form 6-K filing. This press r
• Addex Therapeutics Files Form 6-K with Press Release — 6-K · Apr 17, 2025 Risk: low
  On April 17, 2025, Addex Therapeutics Ltd. issued a press release, incorporated by reference into this Form 6-K filing. This press release is attached as Exhibi
• Addex Therapeutics Files 6-K, Incorporates Exhibits — 6-K · Nov 22, 2024 Risk: low
  Addex Therapeutics Ltd. filed a Form 6-K on November 22, 2024, incorporating Exhibits 99.1 and 99.2 into its existing S-8 registration statements (Registration
• Addex Therapeutics Files 6-K, Incorporates Press Release — 6-K · Nov 12, 2024 Risk: low
  Addex Therapeutics Ltd. filed a Form 6-K on November 12, 2024, reporting a press release issued on November 11, 2024. This filing is incorporated by reference i
• Addex Therapeutics Files 6-K, Incorporates Exhibits — 6-K · Sep 30, 2024 Risk: low
  Addex Therapeutics Ltd. filed a Form 6-K on September 30, 2024, to report information as a foreign private issuer. This filing incorporates by reference exhibit
• Addex Therapeutics Files 6-K with Press Release — 6-K · Sep 19, 2024 Risk: low
  On September 19, 2024, Addex Therapeutics Ltd. announced the issuance of a press release. This press release is incorporated by reference into their Form 6-K fi
• Addex Therapeutics Files 6-K with Press Release — 6-K · Aug 27, 2024 Risk: low
  On August 27, 2024, Addex Therapeutics Ltd. filed a Form 6-K, incorporating by reference a press release dated the same day. This filing serves as a report of a
• Growth Equity Fund Adjusts Addex Therapeutics Stake — SC 13D/A · Aug 14, 2024 Risk: medium
  On August 14, 2024, Growth Equity Opportunities Fund IV, LLC filed an amendment to its Schedule 13D, reporting a change in beneficial ownership of Addex Therape
• Growth Equity Fund Updates Addex Therapeutics Stake — SC 13D/A · Aug 5, 2024 Risk: medium
  On August 5, 2024, Growth Equity Opportunities Fund IV, LLC filed an amendment (No. 6) to its Schedule 13D regarding Addex Therapeutics Ltd. The filing indicate
• Addex Therapeutics Files 6-K with Press Release — 6-K · Jul 22, 2024 Risk: low
  On July 22, 2024, Addex Therapeutics Ltd. announced the issuance of a press release. This press release is incorporated by reference into their Form 6-K filing
• Addex Therapeutics Files 6-K with Press Release — 6-K · Jul 15, 2024 Risk: low
  On July 15, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, incorporated as Exhibit 99.1 to this Form 6-K filing. This press release is
• Addex Therapeutics Files Form 6-K with Press Release — 6-K · Jul 1, 2024 Risk: low
  On July 1, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, which is incorporated by reference into this Form 6-K filing. The press rele
• Addex Therapeutics Files 6-K, Incorporates Exhibits — 6-K · Jun 6, 2024 Risk: low
  Addex Therapeutics Ltd. filed a Form 6-K on June 6, 2024, incorporating by reference Exhibits 99.1 and 99.2 into its existing registration statements on Form F-
• Addex Therapeutics Files 6-K with Press Release — 6-K · Jun 5, 2024 Risk: low
  On June 5, 2024, Addex Therapeutics Ltd. announced the issuance of a press release. This press release is attached as Exhibit 99.1 to the Form 6-K filing and is
• Addex Therapeutics Files 6-K, Incorporates Press Release — 6-K · Apr 29, 2024 Risk: low
  On April 29, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, incorporated by reference as Exhibit 99.1 to this Form 6-K filing. This pr
• Addex Therapeutics Files 6-K with Press Release — 6-K · Apr 18, 2024 Risk: low
  On April 18, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, which is incorporated by reference into this Form 6-K filing. This press r
• Addex Therapeutics Ltd. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Apr 18, 2024 Risk: low
  Addex Therapeutics Ltd. (ADXN) filed a Foreign Annual Report (20-F) with the SEC on April 18, 2024. Addex Therapeutics Ltd. filed its annual report on Form 20-F
• Addex Therapeutics Files 6-K, Incorporates Press Release — 6-K · Apr 3, 2024 Risk: low
  On April 3, 2024, Addex Therapeutics Ltd. announced the issuance of a press release. This press release is incorporated by reference into their Form 6-K filing
• Addex Therapeutics Terminates Cantor Fitzgerald Sales Agreement — 6-K · Jan 30, 2024
  Addex Therapeutics Ltd. terminated its "Controlled Equity Offering SM Sales Agreement" with Cantor Fitzgerald & Co. on January 29, 2024, effective immediately.

Frequently Asked Questions